NRAS and non-small cell lung carcinoma: Interestingly, using TKI-resistant NSCLC cell lines, Eberlein et al. discovered that certain NRAS mutations and NRAS copy number gain are a frequent mechanism of resistance to erlotinib and osimertinib.